… development during the course of therapy. As for any antimicrobial drugs the drug exposure
indices associated with the response of Mycobacterium tuberculosis … growing, extracellular …

… Tuberculosis (TB) caused by Mycobacterium tuberculosis is the … Pharmacokinetic/pharmacodynamic
(PK/PD) models are … tuberculosis growth, during the course of this and our other …

… - and slow-growing Mycobacterium tuberculosis over time (… tuberculosis only exists as a
single (slow-growing) state, all bacteria grow in conditions that correspond to the extracellular …

… replicating and nonreplicating Mycobacterium tuberculosis (2, … intracellular bacilli, while
the chronic C3HeB/FeJ model … detailed mathematical model of mycobacterial growth in the …

… tuberculosis, there is a lack of pharmacokinetic/pharmacodynamic (PK/PD) studies …
collected to determine the bacterial growth using the mycobacterial growth indicator tube (MGIT) …

… We used pharmacokinetic-pharmacodynamic modelling to quantify … in adults and
Mycobacterium tuberculosis is becoming the … Sustainable Development Goals aim to eradicate the …

… maximum number of bacterial growth allowed by the system, … antibacterial effect against
Mycobacterium tuberculosis in the … the intracellular environment to the extracellular environment…

… Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), … Previous pharmacokinetic-pharmacodynamic
(PK–PD) … in vitro Mtb growth and kill rates in both intracellular and extracellular …

… identify the pharmacokinetic/pharmacodynamic parameters … to be effective against
Mycobacterium tuberculosis. Minocycline … Figure 1(a) shows the growth and kill curves of …

… Based on our model, a 10-fold infectious dose would only increase the maximal immune …
/c mouse infection model, since the infecting bacilli are virtually all intracellular, residing in the …